The effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment: a prospective, randomized, and controlled study

Enver Fekaj, Arben Gjata, Mehmet Maxhuni, Enver Fekaj, Arben Gjata, Mehmet Maxhuni

Abstract

Background: In patients with obstructive jaundice, multi-organ dysfunction may develop.

Methods/design: This trial is a prospective, open-label, randomized, and controlled study with the objective to evaluate the effect of ursodeoxycholic acid in liver functional restoration in patients with obstructive jaundice after endoscopic treatment. The aim of this study is to evaluate the effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice after endoscopic treatment. The hypothesis of this trial is that patients with obstructive jaundice, in which will be administered UDCA, in the early phase after endoscopic intervention will have better and faster functional restoration of the liver than patients in the control group.Patients with obstructive jaundice, randomly, will be divided into two groups: (A) test group in which will be administered ursodeoxycholic acid twenty-four hours after endoscopic procedure and will last fourteen days, and (B) control group.Serum-testing will include determination of bilirubin, alanine transaminase, aspartate transaminase, gama-glutamil transpeptidase, alkaline phosphatase, albumin, and cholesterol levels. These parameters will be determined one day prior endoscopic procedure, and on the third, fifth, seventh, tenth, twelfth and fourteenth days after endoscopic intervention.

Discussion: This trial is a prospective, open-label, randomized, and controlled study to asses the effect of ursodeoxycholic acid in liver functional restoration of patients with obstructive jaundice in the early phase after endoscopic treatment.

Trial registration: ClinicalTrials.gov NCT01688375.

References

    1. Roche SP, Kobos R. Jaundice in the adult patient. Am Fam Physician. 2004;69(2):299–304.
    1. Rerknimitr R, Kullavanijaya P. Operable malignant jaundice: To stent or not to stent before the operation? World J Gastrointest Endosc. 2010;2(1):10–14. doi: 10.4253/wjge.v2.i1.10.
    1. Yi-Jun Y, Jing-Sen SH, Shu-Min X, De-Ting ZH, Bing-Sheng C. Effects of different drainage procedures on levels of serum endotoxin and tumor necrosis factor in patients with malignant obstructive jaundice. HBPD Int. 2003;2:426–430.
    1. Scott-Conner CE, Grogan JB. The pathophysiology of biliary obstruction and its effect on phagocytic and immune function. J Surg Res. 1994;57(2):316–336. doi: 10.1006/jsre.1994.1151.
    1. Assimakopoulos SF, Scopa CD, Vaginos CE. Pathophysiology of increased intestinal permeability in obstructive jaundice. World J Gastroenterol. 2007;13(48):6458–6464. doi: 10.3748/wjg.13.6458.
    1. Naranjo A, Cruz A, Lopez P, Chicano M, Martin-Malo A, Sitger-Serra A, Muntane J, Padillo J. Renal function after dopamine and fluid administration in patients with malignant obstructive jaundice. A prospective randomized study. J Gastrointestin Liver Dis. 2011;20(2):161–167.
    1. Van der Gaag NA, Rauws EAJ, Van Eijek CHJ, Maro JB, Van der Harst E, Kubben FJ, Gerritsen JJ, Greve JW, Gerhards MF, de Hingh IH, Klinkenbijl JH, Nio CY, de Castro SM, Busch OR, van Gulik TM, Bossuyt PM, Gouma DJ. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362:129–137. doi: 10.1056/NEJMoa0903230.
    1. Cakir T, Cingi A, Yegen C. Coagulation dynamics and platelet functions in obstructive jaundiced patients. J Gastroenterol Hepatol. 2009;24(5):748–751. doi: 10.1111/j.1440-1746.2009.05801.x.
    1. Fromm H. Gallstone dissolution and the cholesterol-bile acid-lipoprotein axis: Propitious effects of ursodeoxycholic acid. Gastroenterology. 1984;87:229–233.
    1. Bachrach WH, Hofmann AF. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part II Dig Dis Sci. 1982;27:833–856. doi: 10.1007/BF01391378.
    1. Parfitt K. MARTINDALE, The complete drug reference, Volume 32. London: Pharmaceutical Press; 1999. p. 1642.
    1. Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis. 2004;8:67–81. doi: 10.1016/S1089-3261(03)00135-1.
    1. Kowdley KV. Ursodeoxycholic acid therapy in hepatobiliary disease. Am J Med. 2000;108:481–486. doi: 10.1016/S0002-9343(00)00318-1.
    1. Hempfling W, Dilger K, Beuers U. Systematic review: ursodeoxycholic acid—adverse effects and drug interactions. Aliment Pharmacol Ther. 2003;18(10):963–972. doi: 10.1046/j.1365-2036.2003.01792.x.
    1. Copaci I, Micu L, Iliescu L, Voiculesku M. New therapeutical indications of ursodeoxycholic acid. Roman J Gastroenterol. 2005;14(3):259–266.
    1. Hohenester S, Ronald PJ, Elferink O, Beuers U. Primary biliary cirrhosis. Semin Immunopathol. 2009;31(3):283–307. doi: 10.1007/s00281-009-0164-5.
    1. Santos VN, Lanzoni VP, Szejnfeld J, Shigueoka D, Parise ER. A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid. Braz J Med Biol Res. 2003;36(6):723–729. doi: 10.1590/S0100-879X2003000600007.
    1. Willot S, Uhlen S, Michaud L, Briand G, Bonnevalle M, Sfeir R, Gottrand F. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia. Pediatrics. 2008;122(6):1236–1241. doi: 10.1542/peds.2008-0986.
    1. Abbas G, Lindor KD. Pharmacological treatment of biliary cirrhosis with ursodeoxycholic acid. Expert Opin Pharmacother. 2010;11(3):387–392. doi: 10.1517/14656560903493460.
    1. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, Harnois D, Jorgensen R, Petz J, Keach J, Mooney J, Sargeant C, Braaten J, Bernard T, King D, Miceli E, Schmoll J, Hoskin T, Thapa P, Enders F. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(3):808–814. doi: 10.1002/hep.23082.
    1. Ranucci G, Cirillo F, Corte CD, Vecchione R, Vallone G, Iorio R. Successful use of ursodeoxycholic acid in nodular regenerative hyperplasia of the liver. Ann Pharmacother. 2011;45(4):20. doi: 10.1345/aph.1P742.
    1. Marciniak B, Kimber-Trojnar Z, Leszezynska-Gorzelak B, Patro-Malysza J, Trojnar M, Oleszezuk J. Treatment of obstetric cholestasis with polyunsaturated phosphatidylcholine and ursodeoxycholic acid. Ginekol Pol. 2011;82(1):26–31.
    1. Kaya O, Ozdemir F, Atli M, Aslan V, Cagatay M, Anlar M, Alper M. The effects of ciprofloxacine and ursodeoxycholic acid on bacterial translocation in obstructive jaundice. Turk J Gastroenterol. 2009;20(3):186–191.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren